PriMera Scientific
Medicine and Public Health
Volume 6 Issue 4 April 2025
ISSN: 2833-5627

Cardio-Kidney-Metabolic Disease: Prevention and Innovation

Type: Research Article
Received: January 29, 2025
Published: April 02, 2025

Citation:
Madhu A Yadav., et al. "Cardio-Kidney-Metabolic Disease: Prevention and Innovation". PriMera Scientific Medicine and Public Health 6.4 (2025): 13-19.

Madhu A Yadav[1]* and Dipesh Trivedi[2]

[1]*DA, DNB, DM.MBA, Cardiac Anaesthesiologist, Sri Padmavthi Childrens Heart Centre, Tirupathi - 517501, Andhra Pradesh, India*

[2]*MS.Mch, Cardio Thoracic Surgeon, Sri Padmavathi Childrens Heart Centre, Tirupati - 517501, India*

***Corresponding Author:** Madhu A Yadav, Sri Padmavthi Childrens Heart Centre, Tirupathi -517501, Andhra Pradesh, India.

Abstract

Cardio-Kidney-Metabolic (CKM) disease represents an interconnected spectrum of cardiovascular, renal, and metabolic dysfunctions that significantly contribute to global morbidity and mortality. Recent advances in biomarkers, including trimethylamine N-oxide (TMAO), neutrophil gelatinase-associated lipocalin (NGAL), and soluble ST2 (sST2), have enhanced the precision of early detection and risk stratification. Emerging innovations in artificial intelligence (AI) have further revolutionized CKM care, enabling dynamic risk prediction, personalized treatment, and real-time monitoring. This article discusses cutting- edge biomarkers, AI-driven prevention strategies, and cost-effective interventions while highlighting the integration of environmental and social determinants into CKM prevention frameworks.

Keywords: Cardio-Kidney-Metabolic Disease; Biomarkers; Artificial Intelligence; Prevention Strategies

Abbreviations

CKM: Cardio-Kidney-Metabolic.
TMAO: Trimethylamine N-Oxide.
NGAL: Neutrophil Gelatinase-Associated Lipocalin.

Introduction

CKM disease has emerged as a pressing global health concern due to its high prevalence, complex interconnections, and associated economic burden. It is characterized by a triad of type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), and atherosclerotic cardiovascular disease (ASCVD), all of which share common pathophysiological drivers, including chronic inflammation, oxidative stress, endothelial dysfunction, and insulin resistance. Recent estimates suggest that up to 90% of adults in the United States may meet criteria for early-stage CKM syndrome, underscoring the urgent need for effective prevention strategies [1, 2].

Traditional CKM management has been reactive, focusing on treating established disease rather than addressing the systemic interdependencies of its components. However, advances in pharmacological therapies, biomarkers, and AI-driven tools are enabling earlier interventions and precision care. This article explores these innovations, with a focus on advanced CKM biomarkers and AI's role in prevention, and proposes a stage-specific, cost- effective prevention framework.

Advances in CKM Biomarkers

Biomarkers have become indispensable in CKM prevention, offering insights into disease mechanisms, risk stratification, and therapeutic efficacy. Advanced biomarkers are now enabling earlier detection of CKM risk and improving personalization of care.

Trimethylamine N-Oxide (TMAO)

TMAO, a gut-derived metabolite, has emerged as a central player in CKM pathophysiology. Produced through the metabolism of dietary choline and carnitine by gut microbiota, elevated TMAO levels are associated with increased vascular stiffness, endothelial dysfunction, and thrombosis. Recent studies have demonstrated that microbiota-targeted interventions, such as probiotics, can reduce TMAO levels and mitigate cardiovascular and renal risks, offering a cost-effective preventive strategy [3, 4].

Soluble ST2 (sST2)

sST2, a marker of myocardial strain and fibrosis, has been identified as a robust predictor of adverse cardiovascular outcomes. Unlike traditional markers, sST2 reflects dynamic myocardial remodeling, making it particularly valuable in monitoring CKM progression and tailoring therapeutic interventions. Its incorporation into CKM care frameworks can improve early risk identification and guide treatment optimization [5].

Neutrophil Gelatinase-Associated Lipocalin (NGAL)

NGAL has gained prominence as an early marker of kidney injury. Elevated NGAL levels often precede an increase in serum creatinine, allowing for earlier intervention to prevent CKD progression. By integrating NGAL testing into CKM prevention protocols, clinicians can initiate nephroprotective therapies at the earliest stages of renal dysfunction [6].

Advanced Imaging Biomarkers

Emerging imaging technologies, such as coronary artery calcium (CAC) scoring and AI- enhanced echocardiography, are providing non-invasive methods for detecting subclinical CKM disease. These tools enable earlier diagnosis and improve the precision of risk stratification [7].

Artificial Intelligence in CKM Prevention

AI is revolutionizing CKM care by transforming data into actionable insights, optimizing resource allocation, and enabling real-time monitoring. Its applications span risk prediction, diagnostic accuracy, personalized medicine, and public health interventions.

AI-Driven Risk Prediction Models

AI algorithms have significantly improved risk stratification by integrating clinical, genomic, and biomarker data. For example, predictive models incorporating TMAO and NGAL levels outperform traditional statistical methods in identifying individuals at high risk of CKM progression. AI-powered platforms can dynamically adjust risk predictions based on new patient data, enabling proactive interventions [7].

AI in Imaging and Diagnostics

Advanced imaging techniques enhanced by AI, such as automated CAC scoring and echocardiographic analysis, have improved diagnostic precision for CKM-related complications. These tools can detect subclinical disease earlier than conventional methods, allowing for timely therapeutic interventions [8].

Wearable Health Devices and Remote Monitoring

AI-powered wearable devices provide continuous monitoring of vital metrics, including blood pressure, glucose levels, and heart rate variability. These tools enable early detection of CKM-related complications and improve patient adherence to lifestyle and pharmacological interventions. Recent studies have shown that wearable technology integrated with AI can reduce hospitalizations and improve long-term outcomes in CKM populations [9].

AI in Public Health and Environmental Analytics

AI is being used to integrate environmental determinants, such as air quality and urban density, into CKM prevention models. By correlating pollution indices with CKM-related hospitalizations, AI tools can identify high-risk populations and guide community-level interventions, such as urban greening and pollution reduction programs [10].

Cost-Effective CKM Prevention Strategies

The economic burden of CKM disease necessitates the adoption of cost-effective prevention strategies. Biomarker-based screening, microbiota-targeted therapies, and AI-driven tools offer scalable solutions that can reduce long-term healthcare expenditures.

Biomarker-Based Screening

Integrating advanced biomarkers into routine clinical practice can prevent costly complications by enabling earlier interventions. For instance, NGAL testing allows for the timely initiation of nephroprotective therapies, while TMAO monitoring guides dietary and probiotic-based interventions to reduce cardiovascular risk. These approaches are particularly valuable in low-resource settings where access to advanced imaging and pharmacological therapies may be limited.

Microbiota-Targeted Therapies

Probiotics and dietary modifications targeting gut microbiota have emerged as affordable, scalable interventions for CKM prevention. These therapies reduce TMAO levels and systemic inflammation, addressing key drivers of CKM progression while being accessible to underserved populations.

AI-Enabled Cost Optimization

AI tools enhance the cost-effectiveness of CKM prevention by streamlining risk stratification, optimizing resource allocation, and reducing unnecessary diagnostic procedures. For example, AI-powered platforms can prioritize high-risk patients for advanced diagnostics and interventions, improving healthcare efficiency while minimizing costs.

Environmental and Social Determinants of CKM Disease

Environmental and social determinants play a significant role in CKM disease progression but are often underemphasized in clinical frameworks. Addressing these factors is critical for equitable CKM prevention.

Air Pollution and CKM Risk

Chronic exposure to fine particulate matter (PM2.5) and nitrogen dioxide (NO2) has been linked to systemic inflammation, oxidative stress, and accelerated CKM progression. AI models incorporating air quality data can identify high-risk populations and guide targeted interventions, such as pollution reduction programs and urban greening initiatives.

Food Insecurity and Nutritional Access

Dietary patterns heavily influence CKM risk, with processed foods and limited access to fresh produce exacerbating metabolic dysfunction. AI-driven dietary interventions, including community-level initiatives to improve food access, can address these disparities and reduce CKM prevalence.

Proposed CKM Prevention Framework

To achieve equitable and effective CKM prevention, an integrated, stage-specific framework is essential. This framework emphasizes the use of advanced biomarkers, pharmacological innovations, microbiota-targeted therapies, and AI-driven monitoring tools.

Discussion

The integration of advanced biomarkers, AI-driven tools, and microbiota-targeted therapies is transforming CKM prevention. By addressing environmental determinants and leveraging cost-effective strategies, healthcare providers can reduce CKM-related morbidity and mortality while ensuring equitable access. Collaborative efforts to improve access, affordability, and scalability will be essential for achieving global impact.

Comprehensive CKM Prevention Strategies

Cardio-Kidney-Metabolic (CKM) disease prevention requires a multidimensional approach, integrating pharmacological innovations, lifestyle interventions, advanced biomarkers, and technology-driven tools like artificial intelligence (AI). Below are the key strategies categorized into prevention frameworks:

Stage-Specific Prevention Framework
Stage 0 (No CKM Risk Factors)

- *Lifestyle Modifications*: Promote physical activity, balanced diets, and weight management.
- *Probiotic Supplementation*: Maintain a healthy gut microbiota to prevent the production of trimethylamine N-oxide (TMAO), a metabolite linked to CKM progression.
- *Wearable Health Monitoring*: Encourage the use of wearable devices to monitor vital signs such as heart rate and activity levels, enabling early detection of deviations from optimal health.

Stage 1 (Early Metabolic Risk Factors)

- *Biomarker Screening*: Identify metabolic abnormalities early through markers like TMAO, NGAL, and soluble ST2 (sST2).
- *Pharmacological Interventions*: Introduce statins and antihypertensive medications as needed to control lipids and blood pressure.
- *AI-Enabled Risk Prediction*: Use AI-powered tools for personalized risk stratification and intervention planning.

Stage 2 (Metabolic Syndrome)

- *Pharmacotherapy*: Implement the use of GLP-1 receptor agonists and SGLT2 inhibitors to address hyperglycemia, obesity, and metabolic dysfunction.
- *Advanced Diagnostics*: Utilize coronary artery calcium (CAC) scoring and echocardiography for early detection of subclinical organ damage.
- *Dietary Modifications*: Recommend diets low in choline and carnitine to reduce TMAO levels.

Stage 3 (Subclinical Organ Damage)

- *Anti-Inflammatory Agents*: Deploy colchicine or IL-1β inhibitors to address chronic inflammation.

- *Renal-Specific Therapies*: Introduce nephroprotective agents and monitor for early kidney injury with biomarkers like NGAL.
- *Gene Therapy*: Explore experimental interventions targeting fibrosis or lipid metabolism pathways.

Stage 4 (Symptomatic CKM Disease)

- *Multidisciplinary Care*: Involve cardiologists, nephrologists, and endocrinologists for comprehensive management.
- *Regenerative Therapies*: Investigate and implement regenerative approaches such as stem cell therapy and VEGF-mediated renal repair.
- *AI-Driven Real-Time Monitoring*: Use wearable devices integrated with AI to monitor disease progression and adherence to therapies.

Community and Population-Level Interventions

- *Air Quality Improvement*: Reduce air pollution exposure through urban greening and pollution control policies. Chronic exposure to particulate matter (PM2.5) is a known risk factor for CKM disease progression.
- *Food Access Initiatives*: Enhance access to fresh produce in underserved areas to combat dietary contributors to metabolic syndrome.
- *Public Health Campaigns*: Raise awareness about CKM risk factors, prevention strategies, and the importance of regular health checkups.

Cost-Effective Interventions

- *Probiotics and Dietary Interventions*: Offer low-cost solutions for gut microbiota modulation to reduce systemic inflammation and CKM progression.
- *AI-Guided Resource Allocation*: Optimize healthcare resources by prioritizing high-risk patients for advanced diagnostics and therapies.
- *Generic Formulations*: Advocate for the production and distribution of affordable medications, such as generic versions of SGLT2 inhibitors and GLP-1 receptor agonists.

Environmental and Social Determinants of Health

- *Environmental Risk Monitoring*: Integrate air pollution indices and urban density data into CKM risk prediction models to identify high-risk areas.
- *Social Equity*: Address healthcare disparities by subsidizing diagnostic tests and ensuring equitable access to advanced therapies.

Integration of Artificial Intelligence

- *Predictive Analytics*: Leverage AI to predict CKM progression based on patient data, enabling early interventions.
- *Personalized Care Plans*: Use AI algorithms to tailor treatments based on individual risk profiles, lifestyle factors, and comorbidities.
- *Wearable Integration*: Incorporate real-time health monitoring with AI for dynamic feedback on therapy effectiveness and adherence.

Research and Innovation

- *Biomarker Development*: Invest in the validation and clinical integration of novel biomarkers like TMAO, sST2, and NGAL for risk stratification.
- *Gene Therapy Trials*: Expand research into gene-editing technologies targeting PCSK9, inflammatory pathways, and fibrosis markers.
- *Microbiota Engineering*: Explore synthetic probiotics and microbiome-based therapeutics as preventive tools for CKM disease.

Stage	***Criteria***	***Key Interventions***
Stage 0	No CKM risk factors	Promote healthy life style ,AI-guided lifestyle recommendations, probiotics, wearable health monitoring, and air-quality monitoring. advanced health care and community based prevention compaign.
Stage 1	Early metabolic risk factors	ANNUAL SCREENING -Biomarker screening (TMAO, NGAL), statins, dietary modifications, and AI-enabled adherence tracking.
Stage 2	Metabolic syndrome	GLP-1 RAs, SGLT2 inhibitors, dual incretin therapies microbiota-targeted therapies, and advanced imaging (CAC scoring) to assess subclincal atherosclerosis.
Stage 3	Subclinical organ damage	Anti-inflammatory agents (IL-1β inhibitors), renal- specific therapies,PCSK9 inhibitors for aggressive CVD prevention and genetic and epigenetic profiling to guide personalized therapeutic plans
Stage 4	Symptomatic CKM disease	Multidisciplinary care, regenerative medicine, and AI-driven real-time monitoring and AI integrates patient data to optimize management by teams of cardiologists, nephrologists and endocrinologists. Advanced heart and kidney support devices such as wearable monitors and implanatable senosors.

Table 1: CKM Prevention Frame Work.



Figure 1: CKM Prevention Framework: A Continuous Loop.

Conclusion

Advanced biomarkers, AI-driven tools, and microbiota-based therapies are reshaping CKM prevention. Addressing environmental factors and using cost-effective approaches can significantly reduce CKM-related illness and death while ensuring equitable access. Collaborative efforts to enhance accessibility, affordability, and scalability are vital for achieving global success.

Institutional Affiliations

Sri Padmavathi Childrens Heart Centre, Tirupathi, Andhra Pradesh, India.

Disclosures

Nothing relevant to disclose for any author.

Funding

We don’t have any funding.

References

1. Aggarwal Rahul., et al. “Prevalence of Cardiovascular-Kidney-Metabolic Syndrome Stages in US Adults, 2011-2020”. JAMA 331.21 (2024): 1858.
2. Ndumele Chiadi E., et al. “Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory from the American Heart Association”. Circulation 148.20 (2023): 1606-35.
3. Chen Yan-Yan., et al. “TMAO as a Novel Predictor of Major Adverse Vascular Events and Recurrence in Patients with Large Artery Atherosclerotic Ischemic Stroke”. Clinical and Applied Thrombosis/Hemostasis 28 (2022): 10760296221090503.
4. Al-Obaide Mohammed., et al. “Gut Microbiota-Dependent Trimethylamine-N-Oxide and Serum Biomarkers in Patients with T2DM and Advanced CKD”. Journal of Clinical Medicine 6.9 (2017): 86.
5. Sciatti Edoardo., et al. “Prognostic Value of sST2 in Heart Failure”. Journal of Clinical Medicine 12.12 (2023): 3970.
6. Mishra Jaya., et al. “Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a Biomarker for Acute Renal Injury after Cardiac Surgery”. The Lancet 365.9466 (2005): 1231-38.
7. Jawad KM Tawsik., et al. “AI-Driven Predictive Analytics Approach for Early Prognosis of Chronic Kidney Disease Using Ensemble Learning and Explainable AI”. arXiv:2406.06728, arXiv (2024).
8. Van Velzen Sanne GM., et al. “Deep Learning for Automatic Calcium Scoring in CT: Validation Using Multiple Cardiac CT and Chest CT Protocols”. Radiology 295.1 (2020): 66-79.
9. Xie Yi., et al. “Integration of Artificial Intelligence, Blockchain, and Wearable Technology for Chronic Disease Management: A New Paradigm in Smart Healthcare”. Current Medical Science 41.6 (2021): 1123-33.
10. Wani Atif Khurshid., et al. “Environmental Resilience through Artificial Intelligence: Innovations in Monitoring and Management”. Environmental Science and Pollution Research 31.12 (2024): 18379-95.